FDA Invites Patients to Biosimilar Fee Renewal Chats
Published Date: 12/12/2025
Notice
Summary
The FDA is inviting patients, consumer groups, and other stakeholders to join monthly meetings starting April 2026 to help shape the next Biosimilar User Fee Act, which expires in September 2027. These talks will guide how fees for biosimilar drug makers are collected in the future, ensuring everyone’s voice is heard. If you want in, let the FDA know by January 30, 2026!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
BsUFA Authorization Expires September 2027
The current Biosimilar User Fee Act authorization (BsUFA III) expires in September 2027. The notice states that BsUFA authorizes FDA to collect user fees from the regulated industry to support review of biosimilar biological products and that without new legislation FDA will no longer be able to collect those user fees for future fiscal years.
Patient & Consumer Groups: Join Monthly BsUFA Talks
If you represent a patient or consumer advocacy group, notify the FDA by January 30, 2026 to join monthly stakeholder meetings on reauthorizing the Biosimilar User Fee Act. Meetings are expected to start in April 2026, will be held monthly in person at the FDA White Oak Campus (Silver Spring, MD) and virtually via Microsoft Teams, and in-person participants must be REAL ID compliant.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-22618 — NIH Policy on Enhancing Security Measures for Human Biospecimens
The NIH now requires stronger security for human biospecimens funded by them to protect people and national safety. This affects researchers and labs handling these samples, with new rules effective since October 24, 2025. These changes help stop risky access by foreign countries and don’t add extra costs but do require careful handling.
Next: 2025-22620 — Sunshine Act Meeting
The SEC is hosting a public roundtable on December 16, 2025, to talk about Rule 611 and related trading rules. Anyone interested must register by December 15 to join in person or watch online. This meeting affects investors and traders by discussing important rules that keep markets fair and efficient.